Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02845752 · ClinicalTrials.gov registry record · Phase 4
The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
A Phase 4 study of Chronic Obstructive Pulmonary Disease, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02845752: Completed Phase 4 study of Chronic Obstructive Pulmonary Disease, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
NCT02845752 is a Phase 4 study of Chronic Obstructive Pulmonary Disease that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 14 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02845752, a Phase 4 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activation of the skeletal muscles.
Primary Outcome
Constant work rate (CWR) exercise causes fatigue. Fatigue is measured by the difference between pre-CWR and post-CWR maximal voluntary isokinetic power i.e. how much maximal voluntary isokinetic power declines during CWR. The magnitude of fatigue is measured in watts at the time of the shortest exercise duration in either study arm, which is termed "isotime". A smaller value (in watts) of performance fatigue means that the intervention was associated with less fatigue after a given CWR exercise
Conditions Studied
Interventions
- DRUG Placebo Respimat
- DRUG Stiolto Respimat
Study Locations (1)
California
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 4 |
What the finished NCT02845752 record still lists
NCT02845752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo Respimat is the first listed.
NCT02845752 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02845752 about?
NCT02845752 is a clinical study titled "The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease". The purpose of this study is to determine whether exercise can be prolonged in COPD can by the inhaled bronchodilator Stiolto Respimat. The study will identify whether any endurance benefit is due to reduction in fatigue that originates within the skeletal muscles and/or from effects on neural activ...
What is the current status of trial NCT02845752?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2017-03-01. Estimated completion is 2018-08-06.
What conditions does trial NCT02845752 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT02845752?
The interventions under investigation include: Placebo Respimat (DRUG), Stiolto Respimat (DRUG).
Who is sponsoring clinical trial NCT02845752?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02845752 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02845752's enrollment target sits among peer trials
14 82nd of 86 higher than 5 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
RECRUITING · Phase 4
-
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
COMPLETED · Phase 4
-
Nebulized Hypertonic Saline for Inpatient Use in COPD
COMPLETED · Phase 4
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
RECRUITING
-
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy